Health
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
10
August
2023
|
12:59 PM
Europe/Amsterdam
Not intended for U.S. and UK Media – Two-year topline results from the pivotal study PULSAR:
Summary
Results from PULSAR demonstrate long term efficacy of aflibercept 8 mg with extended dosing intervals reaching up to 24 weeks and vision improvements comparable to Eylea™ (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients randomized at baseline to aflibercept 8 mg 16-week dosing regimen received a mean of 8.2 injections (4.6 fewer than Eylea (aflibercept 2 mg)) over two years / Safety profile of aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) remains comparable to Eylea (aflibercept 2 mg) with no new signals identified
